This trial is testing a new intravesical treatment for high-grade non-muscle invasive bladder cancer (HGTa or CIS, including CIS with concomitant Ta) after transurethral resection of bladder tumor (TURBT) and/or biopsy. The trial will test different dose levels to see what is safe and effective. All subjects will receive 6 weeks of treatment.
2 Primary · 0 Secondary · Reporting Duration: Day 1 to Day 43
18 Total Participants · 1 Treatment Group
Primary Treatment: TARA-002 · No Placebo Group · Phase 1
Age 18+ · All Participants · 4 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: